TABLE 1.
Characteristics of IvIg cohort at first IvIg administration
| Age (years) | <18 (n = 5182) | 18+ (n = 19737) | Total IvIg users (n = 24919) |
|---|---|---|---|
| Sex | |||
| Male | 2850 (55.0) | 9294 (47.1) | 12144 (48.7) |
| Female | 2332 (45.0) | 10443 (52.9) | 12775 (51.3) |
| Race | |||
| White | 2831 (54.6) | 15263 (77.3) | 18094 (72.6) |
| Black | 826 (15.9) | 1997 (10.1) | 2823 (11.3) |
| Hispanic | 55 (1.1) | 109 (0.6) | 164 (0.7) |
| Other | 1327 (25.6) | 2012 (10.2) | 3339 (13.4) |
| Unknown race | 143 (2.8) | 356 (1.8) | 499 (2.0) |
| Setting of IvIg use | |||
| Inpatient | 4441 (85.7) | 15079 (76.4) | 19520 (78.3) |
| Outpatient | 741 (14.3) | 4658 (23.6) | 5399 (21.7) |
| Indication 1 | |||
| High‐dose indications | 3131 (60.4) | 13139 (66.6) | 16270 (65.3) |
| Neurological disease | 239 (4.6) | 5784 (29.3) | 6023 (24.2) |
| Hematological disease | 1673 (32.3) | 7077 (35.9) | 8750 (35.1) |
| Autoimmune disease | 1219 (23.5) | 278 (1.4) | 1497 (6.0) |
| Low‐dose indications | 906 (17.5) | 5178 (26.2) | 6084 (24.4) |
| Immunodeficiency | 709 (13.7) | 4043 (20.5) | 4752 (19.1) |
| Lymphoid/blood 2 | 101 (1.9) | 618 (3.1) | 719 (2.9) |
| Anticancer therapy | 10 (0.2) | 43 (0.2) | 53 (0.2) |
| Sepsis/septicemia | 86 (1.7) | 474 (2.4) | 560 (2.2) |
| Unstated indication | 1145 (22.1) | 1420 (7.2) | 2565 (10.3) |
Data are n (%). IvIg = intravenous immunoglobulin.
1
Mutually exclusive indication per IvIg administration determined by applying the following hierarchy: neurological disease (highest level), hematological disease, autoimmune disease, immunodeficiency, lymphoid/blood, anti‐cancer therapy and sepsis/septicemia.
2
Malignant lymphoid or hematopoietic neoplasm.